Asset Details
Do you wish to reserve the book?
E2F4 as a single multifactorial target against Alzheimer's disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
E2F4 as a single multifactorial target against Alzheimer's disease
Do you wish to request the book?
E2F4 as a single multifactorial target against Alzheimer's disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Paper
E2F4 as a single multifactorial target against Alzheimer's disease
2020,2021
Overview
Alzheimer's disease (AD) has a multifactorial etiology, which requires a single multi-target approach for an efficient treatment. We have focused on E2F4, a transcription factor that regulates cell quiescence and tissue homeostasis, controls gene networks affected in AD, and is upregulated in the brain of Alzheimer's patients and of APP/PS1 and 5xFAD transgenic mice. E2F4 contains an evolutionarily-conserved Thr-motif that, when phosphorylated, modulates its activity, thus constituting a potential target for intervention. Here we show that neuronal expression in 5xFAD mice of a dominant negative form of E2F4 lacking this Thr-motif (E2F4DN) potentiates a transcriptional program consistent with global brain homeostasis. The latter correlates with attenuation of both microglial immune response and astrogliosis, modulation of Aβ proteostasis, and blockade of neuronal tetraploidization. Moreover, E2F4DN prevents cognitive impairment and body weight loss, a known somatic alteration associated with AD. We propose E2F4DN-based gene therapy as a promising multifactorial approach against AD. Competing Interest Statement J.M. Frade is shareholder (8.96% equity ownership) of Tetraneuron, a biotech company exploiting his patent on the blockade of neuronal tetraploidization by E2F4DN as a therapeutic approach against Alzheimer's disease. N.L.S. received her salary from a R&D contract with Tetraneuron, and currently she works for this biotech company. M.R.L. and A.G.G. works for Tetraneuron.
Publisher
Cold Spring Harbor Laboratory Press,Cold Spring Harbor Laboratory
